Abstract: Automated calibration of a machine vision system employs a calibration target assembly mountable to a robotic transfer assembly. An inventory management system includes a robotic transfer apparatus, a calibration target assembly, and a stereo vision assembly. The robotic transfer apparatus includes a support assembly and a transfer assembly. The support assembly is configured for repositioning the transfer assembly relative to the support assembly. The transfer assembly is rotatable relative to the support assembly. The calibration target assembly mountable to the transfer assembly and includes optical calibration targets. The stereo vision assembly is configured for imaging the optical calibration targets to generate calibration image data that is processed to generate calibration data for the machine vision system.

Abstract: The present disclosure is directed to a covalent organic framework comprising repeating units of a moiety comprising Formula (I): wherein X, Y, R, R?, n1, and n2 are as described herein. The present disclosure is also directed to a method of making the covalent organic frameworks and a method of separating rare-earth elements using the covalent organic frameworks.

Abstract: A high-transparent, thermoplastically processable polymer composition is described. In an exemplary embodiment, the polymer composition includes an acrylate organic polymer. The acrylate organic polymer is a copolymer that can include functional groups of hydrocarbon group up to nine carbon atoms, hydroalkyl group, halogenated hydrocarbon groups, aminoalkyl group, aryl group, cycloalkyl group, and/or a combination thereof. The polymer composition may further include a polysilicon compound, polycarbonate polymer, a polyvinyl polymer, a plasticizer, and/or a combination thereof.

Abstract: A high-transparent, thermoplastically processable polymer composition is described. In an exemplary embodiment, the polymer composition includes an acrylate organic polymer. The acrylate organic polymer is a copolymer that can include functional groups of hydrocarbon group up to nine carbon atoms, hydroalkyl group, halogenated hydrocarbon groups, aminoalkyl group, aryl group, cycloalkyl group, and/or a combination thereof. In addition, the polymer composition includes a polysilicon compound of Formula (II), up to 20% by weight. The polymer composition may further include a polycarbonate polymer, a polyvinyl polymer, a plasticizer, and/or a combination thereof.

Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.

Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.

Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.

Abstract: Novel conjugates and immunogens derived from imatinib and monoclonal antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of imatinib or its pharmacologically active salts in biological fluids.

Abstract: Novel conjugates and immunogens derived from imatinib and monoclonal antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of imatinib or its pharmacologically active salts in biological fluids.

Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.

Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.

Abstract: Novel conjugates and immunogens derived from imatinib and monoclonal antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of imatinib or its pharmacologically active salts in biological fluids.

Abstract: Novel conjugates and immunogens derived from imatinib and monoclonal antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of imatinib or its pharmacologically active salts in biological fluids.

Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.

Abstract: Novel conjugates and immunogens derived from imatinib and monoclonal antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of imatinib or its pharmacologically active salts in biological fluids.

Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.

Abstract: Novel conjugates of the pharmaceutically active metabolite of irinotecan and novel immunogens derived from this pharmaceutically active metabolite and monoclonal antibodies generated by these immunogens which are useful in immunoassays for the quantification and monitoring of the pharmaceutically active metabolite of irinotecan in biological fluids.

Abstract: Novel conjugates of the pharmaceutically active metabolite of irinotecan and novel immunogens derived from this pharmaceutically active metabolite and monoclonal antibodies generated by these immunogens which are useful in immunoassays for the quantification and monitoring of the pharmaceutically active metabolite of irinotecan in biological fluids.

Abstract: Novel conjugates and immunogens derived from imatinib and monoclonal antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of imatinib or its pharmacologically active salts in biological fluids.

Abstract: The invention provides methods for evolving a polynucleotide toward acquisition of a desired property. Such methods entail incubating a population of parental polynucleotide variants under conditions to generate annealed polynucleotides comprising heteroduplexes. The heteroduplexes are then exposed to a cellular DNA repair system to convert the heteroduplexes to parental polynucleotide variants or recombined polynucleotide variants. The resulting polynucleotides are then screened or selected for the desired property.